Memphasys (ASX:MEM) completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.
It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.
Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.
It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.
The firm's shares rose past 14% on market close on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。